All In Biotech

Drug Trial Radar · NCT07502378

Effect of Acoltremon Ophthalmic Solution 0.003% on Signs and Symptoms of Ocular Surface Disease in Stage I Neurotrophic Keratopathy Patients With Tear Deficiency

Last checked: Nov 20, 2026Latest source record: Aug 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

50

Planned (sponsor's estimate)

Start

Apr 6, 2026

Primary completion

Mar 31, 2027

Study completion Aug 31, 2027

Sponsor

Lead sponsor
University of South FloridaAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Mar 31, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

STUDY OBJECTIVE To assess if acoltremon 0.003% improves tear production in patients with Stage 1 Neurotrophic Keratopathy.

Conditions

  • Ocular Surface Disease
  • Neurotrophic Keratopathy Stage 1

Interventions

  • Patients will receive topical Acoltremon 0.003% ophthalmic solution BID in both eyes over an 8 week period.Drug

    This is an FDA approved drug. The participants will be educated on the potential instillation site sensation that may occur as reported from the Pivotal Trials and that the sensation may differ between eyes due to the Neurotrophic Keratopathy. Qualified eyes must meet the inclusion and exclusion criteria. If both eyes qualify, then the one with the worst vision will be the study eye. If both eyes have equal visual acuity then the right eye will be the study eye.

  • Alternative would be patient exiting the trial and starting on tears or other standard of care.Other

    This is an open label trial. If the patient does not do well on Acoltremon Ophthalmic Solution, then the participant will be removed from trial and put on standard of care treatment, other than Acoltremon.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Unanesthetized Schirmer TestTime frame: 8 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University of South Florida/Ophthalmology

    Tampa, Florida · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.